Q1 EPS Forecast for Nektar Therapeutics Lifted by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at HC Wainwright upped their Q1 2025 EPS estimates for Nektar Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

A number of other equities research analysts have also issued reports on the stock. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Friday. William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a research note on Thursday. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Trading Up 10.0 %

Shares of NKTR opened at $0.90 on Monday. Nektar Therapeutics has a 12-month low of $0.65 and a 12-month high of $1.93. The firm has a 50-day moving average price of $0.88 and a 200 day moving average price of $1.08. The firm has a market capitalization of $165.42 million, a P/E ratio of -1.07 and a beta of 0.65.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The firm had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million.

Insider Activity at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 46,995 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now directly owns 1,195,710 shares in the company, valued at approximately $1,207,667.10. This trade represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 165,586 shares of company stock valued at $159,990 over the last 90 days. 3.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. Nantahala Capital Management LLC grew its position in Nektar Therapeutics by 90.0% in the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock valued at $7,263,000 after buying an additional 3,700,000 shares during the last quarter. Woodline Partners LP grew its position in Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 3,242,841 shares during the last quarter. Altium Capital Management LLC grew its position in Nektar Therapeutics by 26,172.0% in the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $2,790,000 after buying an additional 2,988,581 shares during the last quarter. 22NW LP purchased a new position in Nektar Therapeutics in the 4th quarter valued at $2,038,000. Finally, Eventide Asset Management LLC grew its position in Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after buying an additional 1,870,904 shares during the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.